- Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results